John Kim
Concepts (292)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 15 | 2025 | 677 | 3.690 |
Why?
| | Idiopathic Pulmonary Fibrosis | 20 | 2025 | 697 | 3.250 |
Why?
| | Cardiac Surgical Procedures | 4 | 2022 | 611 | 1.350 |
Why?
| | Cardiopulmonary Bypass | 2 | 2022 | 217 | 1.160 |
Why?
| | Heart Defects, Congenital | 4 | 2021 | 923 | 1.090 |
Why?
| | Sleep Apnea, Obstructive | 3 | 2023 | 300 | 1.070 |
Why?
| | Thrombosis | 2 | 2021 | 398 | 0.920 |
Why?
| | Hemodynamics | 2 | 2021 | 1114 | 0.880 |
Why?
| | HLA-DRB1 Chains | 1 | 2025 | 109 | 0.820 |
Why?
| | Poisoning | 1 | 2025 | 119 | 0.800 |
Why?
| | Shock | 1 | 2025 | 101 | 0.790 |
Why?
| | Lung | 12 | 2025 | 4122 | 0.790 |
Why?
| | Pulmonary Fibrosis | 2 | 2024 | 395 | 0.760 |
Why?
| | Mucin-5B | 2 | 2025 | 234 | 0.760 |
Why?
| | Rheumatic Diseases | 4 | 2024 | 101 | 0.750 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2025 | 370 | 0.740 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 38 | 0.740 |
Why?
| | Pyridones | 2 | 2023 | 210 | 0.740 |
Why?
| | Tomography, X-Ray Computed | 14 | 2025 | 2786 | 0.730 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2023 | 145 | 0.710 |
Why?
| | Pseudomonas Infections | 1 | 2023 | 229 | 0.680 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2021 | 92 | 0.670 |
Why?
| | Biomarkers | 9 | 2025 | 4340 | 0.660 |
Why?
| | ST Elevation Myocardial Infarction | 1 | 2021 | 65 | 0.630 |
Why?
| | Autoimmune Diseases | 4 | 2024 | 467 | 0.610 |
Why?
| | Indoles | 2 | 2023 | 511 | 0.610 |
Why?
| | Resistin | 1 | 2019 | 12 | 0.610 |
Why?
| | Rheumatology | 4 | 2024 | 136 | 0.600 |
Why?
| | Arthritis, Rheumatoid | 3 | 2025 | 1185 | 0.590 |
Why?
| | Asymptomatic Diseases | 1 | 2019 | 102 | 0.580 |
Why?
| | Proteomics | 6 | 2025 | 1203 | 0.580 |
Why?
| | Sleep Deprivation | 1 | 2021 | 207 | 0.570 |
Why?
| | Ketorolac | 1 | 2018 | 33 | 0.550 |
Why?
| | Platelet Aggregation | 1 | 2018 | 99 | 0.540 |
Why?
| | Humans | 63 | 2025 | 146342 | 0.540 |
Why?
| | Leptin | 1 | 2019 | 248 | 0.540 |
Why?
| | Lung Injury | 1 | 2021 | 263 | 0.530 |
Why?
| | Vital Capacity | 4 | 2023 | 293 | 0.530 |
Why?
| | Adiponectin | 1 | 2019 | 243 | 0.530 |
Why?
| | Electrocardiography | 1 | 2021 | 667 | 0.520 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 197 | 0.520 |
Why?
| | Aged | 24 | 2025 | 26432 | 0.510 |
Why?
| | Male | 35 | 2025 | 73396 | 0.450 |
Why?
| | Prospective Studies | 14 | 2025 | 8123 | 0.440 |
Why?
| | Psychotherapy, Brief | 1 | 2015 | 44 | 0.430 |
Why?
| | Female | 36 | 2025 | 79499 | 0.420 |
Why?
| | Cardiovascular Agents | 1 | 2016 | 165 | 0.410 |
Why?
| | Social Work | 1 | 2015 | 84 | 0.410 |
Why?
| | Sleep | 1 | 2021 | 896 | 0.410 |
Why?
| | Tissue Expansion Devices | 1 | 2013 | 5 | 0.390 |
Why?
| | Middle Aged | 23 | 2025 | 36619 | 0.380 |
Why?
| | Breast Implants | 1 | 2013 | 32 | 0.370 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2011 | 263 | 0.360 |
Why?
| | Free Tissue Flaps | 1 | 2013 | 53 | 0.360 |
Why?
| | Matrix Metalloproteinase 7 | 2 | 2023 | 25 | 0.320 |
Why?
| | Mammaplasty | 1 | 2013 | 150 | 0.320 |
Why?
| | Thrombelastography | 3 | 2020 | 182 | 0.310 |
Why?
| | Child | 14 | 2025 | 22693 | 0.310 |
Why?
| | Disease Progression | 5 | 2025 | 2867 | 0.300 |
Why?
| | Critical Care | 1 | 2016 | 706 | 0.300 |
Why?
| | Genome-Wide Association Study | 4 | 2025 | 1537 | 0.300 |
Why?
| | Independent Living | 2 | 2021 | 114 | 0.290 |
Why?
| | Venous Thromboembolism | 2 | 2023 | 332 | 0.280 |
Why?
| | Postoperative Period | 2 | 2021 | 355 | 0.280 |
Why?
| | Atherosclerosis | 2 | 2025 | 410 | 0.280 |
Why?
| | Muscle, Skeletal | 6 | 2011 | 1818 | 0.270 |
Why?
| | Blood Coagulation Disorders | 2 | 2020 | 190 | 0.270 |
Why?
| | Hypertension, Pulmonary | 2 | 2016 | 1957 | 0.260 |
Why?
| | Adolescent | 6 | 2025 | 22557 | 0.240 |
Why?
| | Oxidants | 1 | 2006 | 100 | 0.230 |
Why?
| | Obesity | 1 | 2019 | 3131 | 0.230 |
Why?
| | Smoking | 2 | 2025 | 1486 | 0.220 |
Why?
| | Heart-Assist Devices | 1 | 2021 | 572 | 0.220 |
Why?
| | Antibodies, Antinuclear | 1 | 2025 | 60 | 0.220 |
Why?
| | Child, Preschool | 5 | 2025 | 11913 | 0.220 |
Why?
| | Cohort Studies | 7 | 2025 | 6077 | 0.210 |
Why?
| | Rheumatoid Factor | 1 | 2025 | 177 | 0.200 |
Why?
| | Genetic Predisposition to Disease | 4 | 2025 | 2488 | 0.200 |
Why?
| | Adult | 6 | 2024 | 41087 | 0.200 |
Why?
| | Eicosapentaenoic Acid | 1 | 2023 | 37 | 0.200 |
Why?
| | Smokers | 2 | 2025 | 139 | 0.190 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2025 | 129 | 0.190 |
Why?
| | Carbon Monoxide | 1 | 2023 | 82 | 0.190 |
Why?
| | Demography | 1 | 2024 | 274 | 0.190 |
Why?
| | Glucocorticoids | 2 | 2024 | 536 | 0.190 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2921 | 0.190 |
Why?
| | Peptides, Cyclic | 1 | 2025 | 276 | 0.190 |
Why?
| | Antibody Formation | 1 | 2024 | 290 | 0.180 |
Why?
| | Methylprednisolone | 1 | 2022 | 58 | 0.180 |
Why?
| | Angiopoietin-2 | 1 | 2022 | 15 | 0.180 |
Why?
| | Acetylcysteine | 1 | 2022 | 139 | 0.180 |
Why?
| | Heart Failure | 2 | 2021 | 2329 | 0.170 |
Why?
| | Infant | 5 | 2025 | 10114 | 0.170 |
Why?
| | Insulin | 5 | 2022 | 2525 | 0.170 |
Why?
| | Alleles | 1 | 2025 | 907 | 0.170 |
Why?
| | Vasodilation | 1 | 2025 | 519 | 0.170 |
Why?
| | Myofibroblasts | 1 | 2023 | 149 | 0.170 |
Why?
| | Tomography | 1 | 2021 | 44 | 0.170 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2022 | 91 | 0.170 |
Why?
| | Respiratory System Abnormalities | 1 | 2021 | 18 | 0.170 |
Why?
| | Blood Loss, Surgical | 1 | 2022 | 117 | 0.160 |
Why?
| | Fibrinolytic Agents | 1 | 2023 | 303 | 0.160 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5899 | 0.160 |
Why?
| | Actigraphy | 1 | 2021 | 148 | 0.160 |
Why?
| | Lung Transplantation | 1 | 2024 | 326 | 0.160 |
Why?
| | Femoral Vein | 1 | 2020 | 36 | 0.160 |
Why?
| | Proportional Hazards Models | 4 | 2025 | 1331 | 0.160 |
Why?
| | Photoplethysmography | 1 | 2020 | 12 | 0.160 |
Why?
| | Treatment Outcome | 4 | 2024 | 11821 | 0.160 |
Why?
| | Heart Diseases | 1 | 2023 | 343 | 0.160 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 96 | 0.160 |
Why?
| | Arterial Switch Operation | 1 | 2020 | 16 | 0.160 |
Why?
| | Vital Signs | 1 | 2020 | 39 | 0.150 |
Why?
| | Proof of Concept Study | 1 | 2020 | 90 | 0.150 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2418 | 0.150 |
Why?
| | Promoter Regions, Genetic | 1 | 2025 | 1242 | 0.150 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 55 | 0.150 |
Why?
| | Risk Factors | 5 | 2025 | 10921 | 0.150 |
Why?
| | Body Mass Index | 2 | 2019 | 2458 | 0.150 |
Why?
| | Thorax | 1 | 2020 | 51 | 0.150 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 253 | 0.150 |
Why?
| | Herniorrhaphy | 1 | 2020 | 87 | 0.150 |
Why?
| | Coronavirus | 1 | 2020 | 47 | 0.150 |
Why?
| | Pharmaceutical Services | 1 | 2020 | 76 | 0.150 |
Why?
| | Antibodies, Viral | 1 | 2024 | 689 | 0.150 |
Why?
| | Logistic Models | 1 | 2025 | 2126 | 0.150 |
Why?
| | Adipokines | 1 | 2019 | 56 | 0.150 |
Why?
| | Coronary Angiography | 1 | 2021 | 325 | 0.140 |
Why?
| | Catheterization, Central Venous | 1 | 2020 | 121 | 0.140 |
Why?
| | Peritoneal Dialysis | 1 | 2020 | 100 | 0.140 |
Why?
| | Pulmonary Valve | 1 | 2020 | 100 | 0.140 |
Why?
| | Machine Learning | 1 | 2024 | 594 | 0.140 |
Why?
| | Education, Nursing, Continuing | 1 | 2018 | 46 | 0.140 |
Why?
| | Transcriptome | 2 | 2024 | 1068 | 0.140 |
Why?
| | Oxidative Stress | 3 | 2011 | 1369 | 0.140 |
Why?
| | Acute Disease | 1 | 2021 | 1038 | 0.130 |
Why?
| | Learning Curve | 1 | 2018 | 71 | 0.130 |
Why?
| | Length of Stay | 2 | 2021 | 1358 | 0.130 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 481 | 0.130 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 1 | 2017 | 30 | 0.130 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2020 | 188 | 0.130 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2020 | 293 | 0.130 |
Why?
| | Referral and Consultation | 1 | 2024 | 881 | 0.130 |
Why?
| | Hand | 1 | 2018 | 157 | 0.130 |
Why?
| | Glucose | 6 | 2011 | 1053 | 0.130 |
Why?
| | Autoantibodies | 1 | 2025 | 1500 | 0.130 |
Why?
| | Catheterization, Peripheral | 1 | 2018 | 116 | 0.130 |
Why?
| | Ultrasonography, Interventional | 1 | 2018 | 163 | 0.120 |
Why?
| | Stroke Volume | 1 | 2020 | 652 | 0.120 |
Why?
| | Young Adult | 3 | 2021 | 14330 | 0.120 |
Why?
| | Circadian Rhythm | 1 | 2021 | 515 | 0.120 |
Why?
| | Insulin Receptor Substrate Proteins | 4 | 2011 | 55 | 0.120 |
Why?
| | Microbiota | 1 | 2024 | 725 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2240 | 0.120 |
Why?
| | Polysomnography | 1 | 2017 | 239 | 0.120 |
Why?
| | Scimitar Syndrome | 1 | 2016 | 10 | 0.120 |
Why?
| | Adiposity | 1 | 2021 | 533 | 0.120 |
Why?
| | Simulation Training | 1 | 2018 | 136 | 0.120 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 571 | 0.120 |
Why?
| | Anti-Bacterial Agents | 2 | 2024 | 1942 | 0.120 |
Why?
| | Infant, Newborn | 4 | 2023 | 6460 | 0.120 |
Why?
| | Rats, Zucker | 4 | 2011 | 32 | 0.120 |
Why?
| | Endothelin Receptor Antagonists | 1 | 2016 | 60 | 0.120 |
Why?
| | Coronary Care Units | 1 | 2016 | 27 | 0.120 |
Why?
| | Hemoptysis | 1 | 2016 | 34 | 0.120 |
Why?
| | Nitrous Oxide | 1 | 2016 | 34 | 0.120 |
Why?
| | Algorithms | 2 | 2022 | 1849 | 0.120 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 2113 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 344 | 0.110 |
Why?
| | Insulin Resistance | 3 | 2011 | 1247 | 0.110 |
Why?
| | Linear Models | 1 | 2017 | 857 | 0.110 |
Why?
| | Vaccination | 1 | 2024 | 1449 | 0.110 |
Why?
| | Pilot Projects | 1 | 2021 | 1888 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.110 |
Why?
| | Calcium Channel Blockers | 1 | 2016 | 165 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.110 |
Why?
| | Glycogen Synthase | 4 | 2007 | 6 | 0.110 |
Why?
| | Acute Kidney Injury | 1 | 2022 | 866 | 0.110 |
Why?
| | Health Status | 1 | 2020 | 827 | 0.100 |
Why?
| | China | 1 | 2015 | 280 | 0.100 |
Why?
| | Antiviral Agents | 1 | 2020 | 779 | 0.100 |
Why?
| | Femoral Neoplasms | 1 | 2014 | 10 | 0.100 |
Why?
| | Muscle Neoplasms | 1 | 2014 | 9 | 0.100 |
Why?
| | Vasodilator Agents | 1 | 2016 | 326 | 0.100 |
Why?
| | Hydrogen Peroxide | 4 | 2011 | 337 | 0.100 |
Why?
| | Fever of Unknown Origin | 1 | 2014 | 13 | 0.100 |
Why?
| | Motor Activity | 1 | 2018 | 704 | 0.100 |
Why?
| | Hemangioma | 1 | 2014 | 46 | 0.100 |
Why?
| | Aging | 1 | 2024 | 1996 | 0.100 |
Why?
| | Scleroderma, Systemic | 2 | 2024 | 124 | 0.100 |
Why?
| | Arthralgia | 1 | 2014 | 66 | 0.100 |
Why?
| | Wounds and Injuries | 1 | 2020 | 959 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.080 |
Why?
| | United States | 4 | 2025 | 16136 | 0.080 |
Why?
| | Systemic Inflammatory Response Syndrome | 2 | 2022 | 97 | 0.080 |
Why?
| | Rats | 6 | 2011 | 5586 | 0.080 |
Why?
| | Clinical Competence | 1 | 2018 | 1272 | 0.080 |
Why?
| | Societies, Medical | 2 | 2024 | 907 | 0.080 |
Why?
| | Knee Joint | 1 | 2014 | 453 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2007 | 84 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2020 | 3034 | 0.060 |
Why?
| | Anticoagulants | 2 | 2023 | 746 | 0.060 |
Why?
| | Hypertension | 2 | 2005 | 1272 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8391 | 0.060 |
Why?
| | Retrospective Studies | 5 | 2023 | 17438 | 0.060 |
Why?
| | Free Radicals | 1 | 2006 | 104 | 0.060 |
Why?
| | Renin | 1 | 2005 | 33 | 0.060 |
Why?
| | Critical Illness | 2 | 2023 | 908 | 0.060 |
Why?
| | Mass Screening | 2 | 2024 | 1307 | 0.060 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 39 | 0.060 |
Why?
| | Tetrazoles | 1 | 2005 | 50 | 0.060 |
Why?
| | Biphenyl Compounds | 1 | 2005 | 67 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2025 | 3017 | 0.060 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2024 | 10 | 0.050 |
Why?
| | Spirometry | 1 | 2025 | 234 | 0.050 |
Why?
| | Sjogren's Syndrome | 1 | 2024 | 31 | 0.050 |
Why?
| | Forced Expiratory Volume | 1 | 2025 | 451 | 0.050 |
Why?
| | Walk Test | 1 | 2024 | 82 | 0.050 |
Why?
| | Myositis | 1 | 2024 | 57 | 0.050 |
Why?
| | Mouth | 1 | 2024 | 84 | 0.050 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2023 | 37 | 0.050 |
Why?
| | Vitamin K | 1 | 2023 | 46 | 0.050 |
Why?
| | California | 1 | 2025 | 475 | 0.050 |
Why?
| | Connective Tissue Diseases | 1 | 2024 | 85 | 0.050 |
Why?
| | Proprotein Convertases | 1 | 2023 | 16 | 0.050 |
Why?
| | Multifactorial Inheritance | 1 | 2025 | 243 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 116 | 0.050 |
Why?
| | Blood Proteins | 1 | 2024 | 239 | 0.050 |
Why?
| | Pulmonary Emphysema | 1 | 2025 | 276 | 0.050 |
Why?
| | Serine Endopeptidases | 1 | 2023 | 129 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2024 | 543 | 0.050 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2022 | 31 | 0.040 |
Why?
| | Osteopontin | 1 | 2022 | 37 | 0.040 |
Why?
| | Europe | 1 | 2023 | 421 | 0.040 |
Why?
| | Metalloproteases | 1 | 2022 | 42 | 0.040 |
Why?
| | Quality Improvement | 1 | 2021 | 1354 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2023 | 183 | 0.040 |
Why?
| | Exome | 1 | 2023 | 233 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2024 | 507 | 0.040 |
Why?
| | Child, Hospitalized | 1 | 2022 | 52 | 0.040 |
Why?
| | Anti-Infective Agents | 1 | 2024 | 234 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2024 | 457 | 0.040 |
Why?
| | Survival Analysis | 1 | 2024 | 1378 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 417 | 0.040 |
Why?
| | Biological Transport | 3 | 2007 | 424 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2024 | 731 | 0.040 |
Why?
| | Water-Electrolyte Balance | 1 | 2020 | 37 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2024 | 1503 | 0.040 |
Why?
| | Genetic Variation | 1 | 2025 | 996 | 0.040 |
Why?
| | Pyrazoles | 1 | 2023 | 517 | 0.040 |
Why?
| | Reference Values | 1 | 2020 | 796 | 0.030 |
Why?
| | Hemorrhage | 1 | 2023 | 825 | 0.030 |
Why?
| | Creatinine | 1 | 2020 | 511 | 0.030 |
Why?
| | Gene Expression | 1 | 2023 | 1463 | 0.030 |
Why?
| | Trauma Centers | 1 | 2020 | 441 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2022 | 1051 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2022 | 2070 | 0.030 |
Why?
| | Genotype | 1 | 2022 | 1879 | 0.030 |
Why?
| | Lung Diseases | 1 | 2024 | 787 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.030 |
Why?
| | Fibroblasts | 1 | 2023 | 1034 | 0.030 |
Why?
| | Task Performance and Analysis | 1 | 2018 | 203 | 0.030 |
Why?
| | Nurse's Role | 1 | 2018 | 148 | 0.030 |
Why?
| | Ultrasonography | 1 | 2020 | 788 | 0.030 |
Why?
| | Receptor, Insulin | 2 | 2007 | 92 | 0.030 |
Why?
| | Animals | 6 | 2011 | 38107 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1763 | 0.030 |
Why?
| | Incidence | 1 | 2022 | 2936 | 0.030 |
Why?
| | Signal Transduction | 2 | 2006 | 5246 | 0.030 |
Why?
| | Prognosis | 1 | 2024 | 4351 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2018 | 1135 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 925 | 0.020 |
Why?
| | Phosphoproteins | 2 | 2005 | 320 | 0.020 |
Why?
| | Registries | 1 | 2022 | 2400 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3206 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 3200 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 759 | 0.020 |
Why?
| | Glycogen | 1 | 2007 | 55 | 0.020 |
Why?
| | Skin Neoplasms | 1 | 2014 | 806 | 0.020 |
Why?
| | Pyridines | 1 | 2011 | 610 | 0.010 |
Why?
| | Glucose Transporter Type 4 | 1 | 2005 | 39 | 0.010 |
Why?
| | Angiotensin II | 1 | 2005 | 102 | 0.010 |
Why?
| | Oncogene Proteins | 1 | 2005 | 61 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 983 | 0.010 |
Why?
| | Area Under Curve | 1 | 2005 | 335 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2005 | 248 | 0.010 |
Why?
| | Phosphorylation | 1 | 2007 | 1724 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1041 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2005 | 384 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2005 | 441 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2537 | 0.010 |
Why?
| | Mice | 1 | 2005 | 18297 | 0.000 |
Why?
|
|
Kim's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|